<div id="readability-page-1">10:13 AM EDT, 05/18/2026 (MT Newswires) -- The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022.AstraZeneca ( AZN ) , Novartis ( NVS ) , Novo Nordisk ( NVO ) , Johnson &amp; Johnson's ( JNJ ) Janssen Pharmaceuticals, Bristol Myers Squibb ( BMY ) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.The companies did not immediately respond to requests for comment from MT Newswires.Price: 183.25, Change: +1.67, Percent Change: +0.92 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

The US Supreme Court denied petitions from six major pharmaceutical companies, including AstraZeneca and Johnson & Johnson, challenging the legality of the 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022. The companies did not comment on the decision. The stock price is currently at 183.25, with a change of +1.67 (+0.92%).

Fidelity

AstraZeneca

Johnson & Johnson

iShares US Pharma

Health Care Select Sector SPDR

VG Health

iShares Global Healthcare

AstraZeneca PLC

NOVARTIS AG

Novo Nordisk AS

Bristol Myers Squibb

Novartis AG

Bristol-Myers Squibb Company

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case